Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Gross Margin: 2023-2025

Historic Gross Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to 100.00%.

  • Entrada Therapeutics' Gross Margin changed negligibly% to 100.00% in Q3 2025 from the same period last year, while for Sep 2025 it was 100.00%, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of 100.00% for FY2024, which is negligibly% changed negligibly from last year.
  • Entrada Therapeutics' Gross Margin amounted to 100.00% in Q3 2025, which was down 0.00% from 100.00% recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Gross Margin high stood at 100.00% for Q1 2023, and its period low was 100.00% during Q1 2023.
  • For the 3-year period, Entrada Therapeutics' Gross Margin averaged around 100.00%, with its median value being 100.00% (2025).